Background-New revascularization therapies are urgently needed for patients with severe coronary heart disease who lack conventional treatment options. Methods and Results-We describe a new proangiogenic approach for these no-option patients using adenoviral (Ad) intramyocardial vascular endothelial growth factor (VEGF)-B 186 gene transfer, which induces myocardium-specific angiogenesis and arteriogenesis in pigs and rabbits. After acute infarction, AdVEGF-B 186 increased blood vessel area, perfusion, ejection fraction, and collateral artery formation and induced changes toward an ischemia-resistant myocardial phenotype. Soluble VEGF receptor-1 and soluble neuropilin receptor-1 reduced the effects of AdVEGF-B 186 , whereas neither soluble VEGF receptor-2 nor inhibition of nitric oxide production had this result. The effects of AdVEGF-B 186 involved activation of neuropilin receptor-1, which is highly expressed in the myocardium, via recruitment of G-protein-␣ interacting protein, terminus C (GIPC) and upregulation of G-protein-␣ interacting protein.
S evere coronary heart disease is still a leading cause of death in developed countries in spite of improved management of risk factors and more effective treatments. It is estimated that approximately 5 million people in the United States and the European Union have ischemic heart disease; however, a steadily increasing number of patients fall into a category in which currently available revascularization techniques cannot be applied. This is especially true of elderly patients who have had multiple bypass and stenting operations. 1 It is estimated that these patients represent up to 3% to 5% of all patients in specialty cardiology clinics. Thus, there is a clear need to develop efficient, minimally invasive procedures for the treatment of these no-option patients.
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Therapeutic vascular growth (ie, angiogenesis and arteriogenesis) with genes or proteins has been suggested as an alternative approach for the treatment of these patients. 2 Vascular endothelial growth factors (VEGFs) are potent inducers of vascular growth via binding to 3 tyrosine kinase receptors (VEGFRs). VEGFR-2 is the main regulator of angiogenesis, exerting its function via nitric oxide production, whereas the role of VEGFR-1 is far less defined. 3 VEGF-B 4 and placental growth factor (PlGF) 3 share structural and functional characteristics and bind to VEGFR-1, whereas VEGF-A 5 binds to both VEGFR-1 and VEGFR-2. 3 Figure 1 . AdVEGF-B 186 induces myocardium-specific angiogenic response. A, AdVEGF-B 186 induced angiogenesis in normoxic pig myocardium (a1-a5) and vessel growth in the infarction edge of ischemic myocardium (a6 -a10). Platelet endothelial cell adhesion molecule-1 (PECAM-1) staining for endothelial cells (brown) 6 days after gene transfer, magnification 200ϫ. AdLacZ gene transfer did not have any effect on capillary size or morphology (a1), whereas AdVEGF-A induced a strong angiogenic response in the myocardium (a2), (Continued) VEGF-B has 2 isoforms, VEGF-B 167 and VEGF-B 186 . 4 Both isoforms of VEGF-B, PlGF, and VEGF-A 165 have been shown to bind neuropilin receptor-1 (Nrp-1), 4, 6 but their binding is not identical. VEGF-A 165 binds to 2 different domains of Nrp-1, whereas PlGF only binds to one. 7 Although both isoforms of VEGF-B bind to Nrp-1, the binding of VEGF-B 167 is mediated via a heparin-binding domain, whereas the binding of VEGF-B 186 requires proteolytic processing. 4 Nrp-1 interactions with VEGFRs may alter their signaling properties, 8 and recently, Nrp-1 has also been shown to convey intracellular signaling. 9 In addition, diffusion properties of VEGFs regulate their biological effects. VEGF-A 165 and VEGF-B 167 bind to heparin sulfates, whereas VEGF-B 186 and PlGF are more freely soluble. In addition to enhancing blood flow, the altering of myocardial metabolism and inhibition of apoptosis may also help to protect hibernating myocardium after myocardial infarction. Metabolism is altered in energy-depleted myocardium, and, for example, glycogen accumulation has been shown to protect ischemic myocardium and limit structural damage. 10 Although several angiogenic and metabolic factors have been identified, none has shown relative specificity for the heart. Here, we describe a new cardiac-specific proangiogenic gene therapy approach that could be applicable for the treatment of patients with severe ischemic heart disease.
Methods

Animal Models
Acute myocardial infarction in pigs was induced in the anterolateral wall of the left ventricle by occluding the distal part of the left anterior descending coronary artery with a VortX-18 occlusion coil (Boston Scientific, Natick, Mass). After the appearance of ischemic ECG changes and detection of a wall-motion defect by intracardiac ultrasound (Acunav, Acuson Sequoia, Siemens, Erlangen, Germany), total occlusion of the coronary artery was confirmed by angiography. Hindlimb ischemia was induced in New Zealand White rabbits as described previously. 11
Gene Transfer
Domestic pigs (nϭ121) and New Zealand White rabbits (nϭ68) received an intramuscular or intramyocardial gene transfer of adenoviruses (Ad) encoding human VEGF-A 165 , PlGF-2, VEGF-B 167 , VEGF-B 186 , or a marker gene, LacZ. Experiments were performed in 2 large-animal models to reduce the possibility of species-specific effects. In addition, a subgroup of animals received intramuscular or intramyocardial injections of adenoviruses encoding soluble (s) VEGFR-1, sVEGFR-2, or sNrp-1. In the myocardium, 10 injections with 10 12 viral particles (vp)/mL were given with a custom-made injection catheter in rabbits (injection volume 50 L) and an 8F NOGA catheter system (Biosense Webster, Diamond Bar, Calif), with an injection volume of 200 L in pigs, as described previously. 12 In ischemic pigs, gene transfer was performed 30 minutes after acute myocardial infarction. A total of ten 200-L injections were given around the infarct area, the border zone of the movement defect, and the normally contracting myocardium proximal to the infarction area where collateral vessel formation was expected (referred to as the maximal transduction area). In the hindlimbs, 5 injections with virus concentration of 10 11 vp/mL were given into the semimembranosus muscles (25-gauge needle, volume 0.1 mL in rabbits; 20-gauge needle, injection volume 1 mL in pigs). In ischemic hindlimbs, rectus femoris and tibialis anterior muscles were also transduced. Human clinical GMP-grade (first-generation, serotype 5) replication-deficient adenoviruses analyzed to be free from contaminants were used. The nitric oxide synthase inhibitor L-NAME (N G -nitro-L-arginine methyl ester; 50 mg · kg Ϫ1 · d Ϫ1 ; Sigma-Aldrich, St. Louis, Mo) was given to a subgroup of animals twice a day after the gene transfer. Propofol and fentanyl were used induced capillary growth (a4 and a5, respectively). Endogenous angiogenesis was observed in the infarction edge of ischemic myocardium (infarction scar indicated by ૽) 6 days after infarction and gene transfer in AdLacZ-transduced animals (a6). In AdVEGF-A-transduced animals, vessels were significantly larger in the infarction edge (a7). Lacunae and large glomerular structures were also observed (data not shown). Modest angiogenic response was observed with AdPlGF-and AdVEGF-B 167 -transduced animals (a8 and a9, respectively). AdVEGF-B 186 induced an efficient angiogenic response in the border zone, with thick-walled vessels with an arteriolar phenotype (a10). B and C, AdVEGF-B 186 induced a significant increase in mean capillary area in healthy (B) and ischemic (C) myocardium. B, In the maximal transduction areas of AdVEGF-A-transduced myocardium, mean capillary area was increased by 5.1-fold compared with AdLacZ controls (PECAM-1 staining, magnification 200ϫ). AdPlGF induced a similar but slightly weaker angiogenic response (increase in mean capillary size 3.2-fold compared with AdLacZ controls). Both AdVEGF-B 167 and AdVEGF-B 186 induced angiogenesis in the myocardium, although the effect was greater in AdVEGF-B 186 -transduced animals (2.8-fold compared with AdLacZ controls). C, In the infarction edge, AdVEGF-A gene transfer led to a 2.2-fold increase in vessel area, AdPlGF and AdVEGF-B 167 gene transfer led to a 1.4and 1.6-fold increase, respectively; AdVEGF-B 186 gene transfer induced the largest (2.9-fold) increase in mean vessel area among the VEGFs compared with the AdLacZ control. D and E, AdVEGF-B 186 did not induce angiogenesis in either normoxic or ischemic skeletal muscle, whereas VEGF-A and PlGF were angiogenic (D, d1-d10. and E). AdLacZ did not change capillary size or morphology 6 days after gene transfer (d1 and d6). AdVEGF-A (d2 and d7) and AdPlGF (d3 and d8) induced a robust angiogenic response in normoxic skeletal muscle (20-and 43-fold increase in capillary size [e] compared with AdLacZ, respectively) and ischemic skeletal muscle. AdVEGF-B 167 and AdVEGF-B 186 were ineffective in both settings (d4, d5, d9, and d10). AdVEGF-B 186 did not increase perfusion in skeletal muscle (d11-d15). Perfusion measured by contrast-enhanced ultrasound imaging (CEU) 6 days after gene transfer showed significant increases in perfusion in AdVEGF-A-transduced (d12) and AdPlGF-transduced (d13) animals (29-and 44-fold compared with AdLacZ, respectively). Both AdVEGF-B 167 and AdVEGF-B 186 were ineffective (d14 and d15). Quantification of CEU is found in supplementary Figure I . F and G, VEGFR-1 ligands differentially stimulated cell proliferation in the pig myocardium (f and g1-g5). Double staining for PECAM-1 (blue) and proliferating cell nuclear antigen (PCNA; brown), showed very few proliferating cells in AdLacZtransduced hearts (g1; magnification 400ϫ). AdVEGF-A induced a strong proliferative response (g2), with a 15-fold increase in proliferative cells/field compared with AdLacZ in the maximally transduced area, and most of these were endothelial cells (F). A similar but slightly weaker effect was observed in AdPlGF-transduced hearts (g3 and F). AdVEGF-B 167 had only a weak effect on cell proliferation (g4). In contrast, in AdVEGF-B 186 -transduced myocardium, the total number of proliferating cells was comparable to AdVEGF-A, but the distribution between the different cell types was strikingly different, with the majority of the PCNA-positive nuclei being nonendothelial cells in the perivascular space (g5, F). g6 -g10, VEGFR-1 ligands displayed differences in pericyte recruitment in the pig myocardium. Double staining for PECAM-1 and ␣-smooth muscle actin (␣-SMA) revealed unique characteristics for all groups (magnification 400ϫ). In AdLacZ-transduced myocardium, PECAM-1-positive capillaries (brown) were surrounded by a thin layer of ␣-SMA-positive mural cells (blue; g6). AdVEGF-A-and AdPlGF-induced capillaries were thick-walled and had almost complete, thick pericyte coating (g7 and g8). AdVEGF-B 167 -induced capillaries were thin-walled and had only partial pericyte coverage (g9). In AdVEGF-B 186 -transduced hearts, ␣-SMA-positive staining was observed both in mural cells (arrowheads) and in the perivascular space, possibly due to the proliferation of mural cells (g10). **PϽ0.01 and ***PϽ0.001 for endothelial cells; ###PϽ0.001 for other cell types. for pig anesthesia and medetomidin and ketamine for rabbit anesthesia. All animal experiments were approved by the Experimental Animal Committee, University of Kuopio.
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Echocardiography and Contrast-Enhanced Ultrasound Imaging of Perfusion
Echocardiography was performed at baseline, after acute myocardial infarction, and before animals were euthanized on day 6 after gene transfer with an Acunav catheter inserted into the right atrium. Ejection fraction was quantified with ultrasound. Contrast-enhanced ultrasound perfusion measurement was done in skeletal muscles as described previously 13 after a bolus injection of a contrast agent (SonoVue, Bracco, Milan, Italy) via the ear vein.
Microsphere Perfusion and Angiography
Myocardial perfusion was measured with red fluorescent microsphere particles (Molecular Probes/Invitrogen, Carlsbad, Calif; 15 m, 5ϫ10 6 particles) as described previously. 12 Angiography of the left anterior descending coronary artery to visualize collateral vessels was performed at the time of euthanasia (Siremobil 2000, Siemens). The last images before venous filling are shown.
Blood Vessel Measurements
Mean blood vessel area (m 2 ) was measured from CD31-immunostained sections of rabbit muscles 13 and platelet and endothelial cell adhesion molecule-1-stained pig muscle sections at 200ϫ magnification. Vessels from the infarction edge were analyzed at 100ϫ magnification. All measurements were performed with AnalySIS software (Soft Imaging System) in a blinded manner from 5 to 10 different randomly selected fields from each section. Means of the measurements are reported.
Immunoprecipitation and Western Blot
Snap-frozen tissue samples from normoxic and ischemic transduced myocardium and skeletal muscles were homogenized in protein extraction buffer (T-Per, Pierce, Rockford, Ill). Immunoprecipitations were done with Nrp-1 antibody (C-19, Santa Cruz Biotechnology, Santa Cruz, Calif) and protein A Sepharose (Amersham Biosciences, Uppsala, Sweden). Immunoblotting from native samples was performed with antibodies for Nrp-1 (C-19, Santa Cruz Biotechnology) and G-protein-␣ interacting protein (GAIP, N-17, Santa Cruz Biotechnology) and from Nrp-1-immunoprecipitated samples with antibodies for VEGF-B (MAB 3373, R&D Systems, Minneapolis, Minn) and GAIP-interacting protein (GIPC; N-19, Santa Cruz Biotechnology).
Statistical Analyses
Results are expressed as meanϮSEM. Statistical significance was evaluated with linear mixed models (SPSS version 14.0, SPSS, Inc, Chicago, Ill), which are based on generalized estimating equations, or by ANOVA followed by Student's t test. PϽ0.05 was considered statistically significant. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
AdVEGF-B 186 Induces Myocardium-Specific Angiogenesis
It has remained unknown which growth factor(s) might be best suited for the treatment of myocardial ischemia. 1, 2, 12, 13 In the present study, we tested several VEGFR-1 ligands side by side in large-animal models using a new pig infarction model based on a percutaneous coil-mediated occlusion of the left anterior descending coronary artery. The infarction area was confirmed with a wall-motion defect and ECG changes. In contrast to previous infarction models based on thoracotomy and surgical coronary occlusion, this model preserves an intact pericardium, avoids excess fibrous scar formation in the thorax and around the heart, and allows precise imaging of the myocardium with ultrasound. Gene delivery was done percutaneously into the infarction border zone and adjacent myocardium with a NOGA mapping-injection catheter. 12 Of the VEGFR-1 ligands (VEGF-B 167 , VEGF-B 186 , PlGF, and VEGF-A 165 ), both VEGF-B isoforms showed angiogenic effects only in the myocardium ( Figure 1A through 1E ). Both in normal and in ischemic skeletal muscles, the 2 AdVEGF-B isoforms were ineffective ( Figure 1D , d4 -5, d9 -10, and d14 -15), whereas AdVEGF-A and AdPlGF had significant angiogenic effects that increased tissue perfusion ( Figure 1D , d2, d7, and d12 and d3, d8, and d13, respectively; Data Supplement Figure I ). AdVEGF-B 186 was particularly efficient in myocardium after acute myocardial infarction ( Figure  1A , a6 through a10). Mean vessel size in the infarction border zone was increased almost 3-fold compared with the AdLacZ controls ( Figure 1C ). AdPlGF also increased the mean vessel number in the infarction edge ( Figure 1A, a8 and data not shown), but the increase in mean vessel area was not significant ( Figure 1C ). The angiogenic effects of AdVEGF-B 186 and AdVEGF-A persisted in the maximal transduction area in the periinfarct zone 3 weeks after gene therapy (Data Supplement Figure II ). Transient production of angiogenic factors by adenoviral overexpression is therefore sufficient to induce angiogenic neovessels that are further regulated by blood flow and the metabolic needs of the surrounding tissue.
The angiogenic phenotypes induced by the different VEGFs were clearly distinct. AdVEGF-B 186 predominantly stimulated proliferation of abundant ␣-smooth muscle actin-positive cells ( Figure 1F and 1G, g5 and 1g10), whereas AdPlGF and AdVEGF-A mainly induced proliferation of endothelial cells (Figure 1F and 1G, g2 and 1g3) in normal myocardium. AdVEGF-B 167 -induced vessels had low pericyte coverage, and only a few proliferating endothelial cells were seen ( Figure 1F and 1G, g4 and  g9) . Thus, the effects of AdVEGF-B 186 in the myocardium were clearly different from the other VEGFs.
AdVEGF-B 186 -induced angiogenesis also improved the functional outcome in the myocardial ischemia model. AdVEGF-B 186 induced the formation of angiographically visible collateral arteries around the infarction area ( Figure  2A ). Ejection fraction improved by 18% and 21% after AdVEGF-B 186 and AdVEGF-A treatments, respectively (Figure 2B) , as well as blood flow in the myocardium as measured by microsphere trapping ( Figure 2C ). Thus, Ad-VEGFB 186 treatment is a promising new candidate for acute myocardial infarction treatment because of its unique myocardium-specific properties.
AdVEGF-B Induces Angiogenesis Through VEGFR-1 and Nrp-1 but Not VEGFR-2
Even though both VEGF-B 186 and PlGF bind to VEGFR-1, the angiogenic effects induced by these 2 ligands were clearly distinct. The effect of AdVEGF-B 186 was dependent on VEGFR-1, but unlike AdPlGF, it was not dependent on VEGFR-2 or upregulation of endogenous VEGF-A, as determined by simultaneous transductions with AdsVEGFR-1 or AdsVEGFR-2 ( Figure 3A through 3D) . Moreover, angiogenesis induced by AdVEGF-B 186 was not blocked by inhibition of nitric oxide production by L-NAME, which completely inhibits the angiogenic effects of AdPlGF and AdVEGF-A (Data Supplement Figure III) . The angiogenic effects of AdVEGF-B 186 in normal myocardium were instead dependent on membrane-bound Nrp-1, because AdsNrp-1 significantly reduced AdVEGF-B 186 -induced capillary growth ( Figure 3E , e4, and 3F). Interestingly, AdsNrp-1 enhanced the angiogenic effects of AdVEGF-A (Figure 3Em , e3, and 3F), which may be due to enhanced VEGFR-2 activity, 14 further suggesting different angiogenic mechanisms for VEGFR-1 and VEGFR-2.
Mechanistic studies were also performed in ischemic myocardium. AdsNrp-1 increased mean vessel area by 2.3fold compared with AdLacZ ( Figure 3G , g3, and 3H), which was likely due to an enhancement of the vessel growth induced by endogenous VEGF-A produced in the ischemic tissue (data not shown). In contrast, AdVEGF-B 186 -induced angiogenesis was reduced both by AdsNrp-1 (by 69%; Figure  3G , g4) and by AdsVEGFR-1 (by 47%; Figure 3G , g6).
In line with the cardiac-specific effects of VEGF-B 186 , Nrp-1 was abundantly present in both normal ( Figure 4A and 4B) and ischemic myocardium (data not shown) but not in skeletal muscle ( Figure 4A and 4B) . In AdLacZ-, AdVEGF-A-, and AdPlGF-transduced hearts, Nrp-1 was observed mainly in the capillary endothelium in the angiogenic area and in the endothelial layer of arteries and small veins ( Figure  4A , a5 through a7), whereas in AdVEGF-B 186 -transduced myocardium, expression was also seen in cardiomyocytes ( Figure 4A, a8 and a12 ). Western blot analysis confirmed strong expression of Nrp-1 in both AdLacZ-and AdVEGF-B 186 -transduced myocardium but not in skeletal muscle (Figure 4B) .
The role of Nrp-1 in VEGF-B 186 -induced cardiac angiogenesis warranted analysis of the intracellular signaling events downstream of the VEGF-B 186 binding to Nrp-1. Immunostainings, Western blotting, and pull-down assays of GIPC, an intracellular Nrp-1 adaptor protein, 9 and GAIP, a GIPC interacting protein and a regulator of G-protein signaling (also known as RGS19), were performed. GIPC expression was mainly localized to endothelial cells in AdLacZ-, AdVEGF-A-, and AdPlGF-transduced myocardium ( Figure  4C , c5 through c7), whereas no expression was detected in skeletal muscle ( Figure 4C , c1 through c4); however, in AdVEGF-B 186 -transduced hearts, polarized GIPC expression was also found in the cardiomyocytes (Figure 4C, c12) .
VEGF-B 186 bound to Nrp-1 in AdVEGF-B 186 -transduced myocardial samples, as shown by pull-down assays of tissue lysates with Nrp-1 antibodies followed by Western blotting with antibodies to VEGF-B ( Figure 4D ). Pull-down assays with Nrp-1 antibodies also showed GIPC binding to Nrp-1 in AdVEGF-B 186 -transduced myocardium but not in skeletal muscle ( Figure 4E ). Only small amounts of Nrp-1-associated GIPC were seen in AdLacZtransduced myocardium ( Figure 4E ), which suggests a VEGF-B-dependent recruitment of GIPC to Nrp-1. Similar activation of Nrp-1 in ischemic myocardium was also confirmed by Western blot (data not shown).
GAIP was expressed in endothelial cells in AdLacZ-, AdVEGF-A-, AdPlGF-, and AdVEGF-B 186 -transduced myocardium ( Figure 4F , f5 through f8). Cardiomyocytes in AdLacZ-, AdVEGF-A-, and AdPlGF-transduced hearts were positive for GAIP ( Figure 4F , f9 through f11); however, in AdVEGF-B 186 -transduced myocardium, a strong polarized, granular GAIP staining was observed in cardiomyocytes in an overlapping staining pattern with Nrp-1 and GIPC ( Figure 4F , f12). Upregulation of GAIP was confirmed by Western blot analyses that showed strong GAIP expression in AdVEGF-B 186 -transduced myocardium but not in AdLacZ-transduced myocardium or skeletal muscle ( Figure 4G ). These findings suggest that Nrp-1 signaling via G proteins at least partially mediates the cardiac effects of VEGF-B 186 and that this effect is specific for VEGF-B compared with the other VEGFs.
AdVEGF-B 186 Induces Secondary Changes in Metabolism and Apoptotic Signaling in Cardiomyocytes
Because proliferation was largely seen in nonendothelial, ␣-smooth muscle actin-positive cells in vivo ( Figure 1F and 1G, g5, and g10), possible effects of VEGF-B on cardiomyo- sVEGFR-1 and sVEGFR-2 also blocked the angiogenic effects of AdVEGF-A in pig myocardium (c3, c5, D). Although PlGF is not a ligand for VEGFR-2, the angiogenic effects of AdPlGF were also blocked by sVEGFR-2, which suggests an angiogenic mechanism dependent on a VEGFR-2 ligand (a4, B). Also, sVEGFR-1 blocked the angiogenic effects of AdPlGF (a6, B) . In contrast, only sVEGFR-1 blocked the angiogenic response of AdVEGF-B 186 in myocardium (c6, D), whereas sVEGFR-2 had no significant effect (c4, D), which indicates that the angiogenic mechanism of AdVEGF-B 186 is dependent on VEGFR-1 and does not involve ligand-induced signaling via VEGFR-2. E and F, sNrp-1 blocked the angiogenic effect of AdVEGF-B 186 but enhanced AdVEGF-A-induced angiogenesis. cyte growth and metabolism were also addressed. Recently, both VEGF-B and Nrp-1 have been implicated in antiapoptotic signaling. 15, 16 We therefore studied apoptosis in the infarction edge of ischemic myocardium using terminal dUTP nick end-labeling staining. The number of apoptotic cells was significantly decreased after AdVEGF-B 186 gene transfer compared with AdLacZ-, AdPlGF-, and AdVEGF-A-transduced hearts (Data Supplement Figure IV) .
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To study whether VEGF-B had a direct antiapoptotic effect on cardiomyocytes or whether it mediated its effects through VEGFR1-and Nrp-1-expressing endothelial cells, bEnd3 endothelial cells and HL-1 cardiomyocytes were studied in vitro. Whereas bEnd3 cells express VEGFR-1, VEGFR-2, and Nrp-1, HL-1 cardiomyocytes express Nrp-1 but do not express VEGFR-1 (data not shown), similar to the situation in vivo. Treatment of HL-1 cardiomyocytes with VEGF-B 186 did not alter levels of the fatty acid transporters Fatp1 and Fatp4 or of the apoptotic factors Bik1, Bmf1, or Bad1 ( Figure 5A ), which suggests that VEGFR-1 indeed is essential for VEGF-B-mediated signaling. In contrast, VEGF-B 186 treatment of bEnd3 endothelial cells increased Fatp4 expression by 1.7fold, whereas it had no direct effect on the apoptotic genes ( Figure 5B ) (C. Rosenlew and U. Eriksson, unpublished data, 2007). Most importantly, we found that although VEGF-B 186 did not have direct effects on cultured cardiomyocytes, conditioned media from both VEGF-B 167 -and VEGF-B 186treated endothelial cells significantly decreased the expression of Bik1, Bmf1, and Bad in cardiomyocytes ( Figure 5C ). These results thus indicate an indirect antiapoptotic effect of both VEGF-B isoforms both in vivo and in vitro, mediated through endothelial cells by unknown soluble factors.
We furthermore assayed for AdVEGF-B 186 -mediated metabolic changes in the myocardium. Fatp4 upregulation was confirmed from the transduced pig myocardium by reverse-transcription polymerase chain reaction ( Figure 5D ) (C. Rosenlew and U. Eriksson, unpublished data, 2007). Higher accumulation of lipids (4-fold compared with AdLacZ) was also observed in cardiomyocytes after AdVEGF-B 186 gene transfer ( Figure 5E , e1 through 5e4, and 5F), whereas fewer lipid droplets were seen in AdVEGF-A-and AdPlGF-transduced hearts ( Figure 5E, e2 and e3 ). Glycogen has been shown to be important for heart metabolism, especially under ischemic conditions, and its accumulation is cardioprotective in the hibernating myocardium. 10 Periodic acid-Schiff staining showed a marked glycogen accumulation in cardiomyocytes after AdVEGF-B 186 gene transfer ( Figure 5F, f8) , whereas smaller amounts of glycogen were observed after AdLacZ, AdVEGF-A, and AdPlGF gene transfers ( Figure 5F, f5 through f7) . Thus, AdVEGF-B 186 , but not transduction of the other VEGFs, led to changes in cardiac metabolism that likely further protected the myocardium after infarction.
On the basis of the findings in both normoxic and ischemic myocardium, we propose a model for VEGF-B function in the heart ( Figure 6 ). Because membrane-bound Nrp-1 appears to be essential for the cardiac effects of AdVEGF-B 186 (Figure 3E, 3F , 3G, and 3H), and Nrp-1 is activated in AdVEGF-B 186 -transduced tissues ( Figure 4E ), VEGF-B 186 functions may be mediated at least in part via recruitment of GAIP to the cell membrane ( Figure 4F, f12 ) and G-protein-mediated signaling.
Discussion
VEGF-B 186 induced a myocardium-specific angiogenic effect that was qualitatively and mechanistically different from that induced by other VEGFR-1 ligands. In previous studies, we have shown that AdVEGF-B 167 and AdVEGF-B 186 do not have any angiogenic effects in periadventitial tissue around carotid arteries. 17 In contrast to our results, VEGF-B has been shown to induce angiogenesis in mouse hindlimb ischemia. 18 This discrepancy may be explained by the use of a small-animal model and differences in capillary growth mechanisms between small-and large-animal species. Interestingly, a recent publication by Li et al 19 also suggests a restricted function for VEGF-B in mouse myocardium. It is interesting to note that VEGF-B-deficient mice appear healthy and fertile and display only minor heart phenotypes. 20, 21 PlGF-deficient mice are also healthy and fertile. 22 Although neither growth factor is regulated by hypoxia, both VEGF-B and PlGF knockout mice are reported to have an impaired angiogenic response in ischemic tissues. 20, 22 However, the specificity of VEGF-B in the myocardium has not been reported previously. GAIP staining was localized to the capillary endothelium in AdLacZ-, AdVEGF-A-, AdPlGF-, and AdVEGF-B 186 -transduced hearts (f5-f8). In addition, a polarized, granular GAIP staining was detected in AdVEGF-B 186 cardiomyocytes (f12). GAIP staining in AdLacZ-(f9), AdVEGF-A-(f10), and AdPlGF-transduced (f11) cardiomyocytes was diffuse. No GAIP expression was found in skeletal muscles (f1-f4). Accordingly, Western blot analysis showed strong expression of GAIP in AdVEGF-B 186 -transduced hearts, whereas expression in AdLacZ-transduced hearts was very low, and no GAIP was detected in skeletal muscle samples (G). L indicates AdLacZ-transduced tissue; B, AdVEGF-B 186 -transduced tissue. In addition to angiogenesis, AdVEGF-B 186 also induced collateral artery growth in the ischemic heart ( Figure 2 ). Collateral artery growth may have been induced by either direct effects on smooth muscle cells ( Figure 1G ) or increased shear stress in collateral arteries induced by increased blood flow in the infarction edge.
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Nrp-1 expression was strongly positive in the capillary endothelium in angiogenic areas and in the endothelium of arterioles and venules in the myocardium, but it was below the detection limit in the skeletal muscles. It is possible that Nrp-1 localizes the downstream effects of VEGF-B 186 to the myocardium because of the differences in Nrp-1 expression in the myocardium and skeletal muscle ( Figure 4A ). Nrp-1 has been shown to be involved in embryonic angiogenesis. 23 In contrast to its functions in the developing nervous system, intracellular signaling events have recently been shown to play a role in angiogenic functions of Nrp-1. 9, 24 Interestingly, AdVEGF-B 186 also induced Nrp-1 expression in cardiomyocytes in the gene transfer area ( Figure 4A ).
In the present study, we showed an activation of the Nrp-1 signaling pathway after AdVEGF-B 186 gene transfer in vivo. In contrast, the effects of AdPlGF were mediated primarily via upregulation of endogenous VEGF-A, which could be blocked by simultaneous transduction with AdsVEGFR-2 ( Figure 3A) . The angiogenic effects of AdVEGF-A and AdPlGF were also blocked by the nitric oxide synthase inhibitor L-NAME, whereas this treatment had no effect on the angiogenic effects of AdVEGF-B 186 . It is therefore likely that AdVEGF-B 186 and AdPlGF induce different signaling events, and AdVEGF-B 186dependent recruitment of the Nrp-1 downstream target molecules GAIP and GIPC to myocardial cell membranes was detected only after AdVEGF-B 186 administration (Figure 4a12 , 4c12, and 4f12). On the basis of cell culture studies, the effects of AdVEGF-B 186 were mediated via endothelial cells, and no direct effect on cultured cardiomyocytes could be detected. Interestingly, VEGF-B 186 also has indirect metabolic effects on cardiomyocytes, increasing Fatp4 expression and lipid and glycogen accumulation in AdVEGF-B 186 hearts, which may make cardiomyocytes more resistant to ischemia. Karpanen at al 25 also recently published a report on the metabolic effects of VEGF-B. However, we cannot exclude other possibilities, such as the presence of a new VEGF receptor, a coreceptor, or another type of structure capable of preferentially binding VEGF-B 186 in cardiac cells, nor can we rule out the possibility of secretion of an unidentified molecule from endothelial cells that mediates the effects of VEGF-B 186 on cardiomyocytes. In addition to Nrp-1 activation, different diffusion kinetics of the transduced growth factors contribute to the different angiogenic profiles, because VEGF-B 186 is known to be freely soluble and capable of diffusing from the site of transduction, whereas VEGF-B 167 and VEGF-A bind tightly to heparan sulfate proteoglycans.
The exact mechanisms for the myocardial specificity of VEGF-B 186 and the collateral artery formation in the AdVEGF-B 186 -treated hearts need to be clarified further; however, the increased proliferation and appearance of apoptosis-resistant cardiomyocytes around the infarction border zone in the Ad-VEGF-B 186 -treated hearts, together with increases in Fatp4 expression and lipid and glycogen accumulation, clearly suggest that VEGF-B 186 may have favorable cardioprotective properties in addition to its unique heart specificity. We conclude that AdVEGF-B 186 is a promising new therapeutic candidate for the treatment of patients with severe coronary heart disease. Results are presented as fold change versus sVEGFR1treated cells set to 1 U. C, Conditioned media from VEGF-B-treated bEnd3 cells downregulated BH3-only genes in cultured HL-1 cardiomyocytes. mRNA levels of BH3-only genes Bik1, Bmf1, and Bad1 in HL-1 cardiomyocytes treated with conditioned media from either VEGF-B 186 -, VEGF-B 167 -, PlGF-, or sVEGFR-1-treated bEnd3 cells. Media from bEnd3 cells treated with either of the VEGF-B isoforms induced significant downregulation of the antiapoptotic genes, whereas media from PlGF-treated bEnd3 cells had no effect. Results are presented as fold change versus bEnd3ϩsVEGFR1-treated cells set to 1 U. D, AdVEGF-B 186 induced a 31-fold upregulation of Fatp4 in vivo in pig myocardium. mRNA expression of Fatp4 in normoxic pig myocardium transduced with AdLacZ or AdVEGF-B 186 is shown. mRNA levels were determined by real-time reverse-transcription polymerase chain reaction and are presented as fold change versus levels in AdLacZ-transduced hearts set to 1 U. E and F, AdVEGF-B 186 gene transfer led to metabolic changes in the myocardium. AdVEGF-B 186 gene transfer, as compared with AdCMV gene transfer, led to a significant increase in lipid accumulation in cardiomyocytes, as observed by oil red O staining (ORO; magnification 200ϫ; e4, F). No such effect was observed with either AdVEGF-A or AdPlGF (e2, e3, F). Increased amounts of glycogen were also detected in cardiomyocytes of AdVEGF-B 186 -transduced myocardium with periodic acid-Schiff (PAS) staining (magnification 200ϫ; e8) compared with AdLacZ-, AdVEGF-A-, or AdPlGF-transduced tissues (e5-e7). *PϽ0.05, **PϽ0.01, and ***PϽ0.001. 
